New study aims to pinpoint which Alzheimer's patients respond best to antibody drug
NCT ID NCT07152418
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will test the antibody drug lecanemab in 120 people with mild cognitive impairment or mild-to-moderate Alzheimer's disease. Using PET scans to measure amyloid and tau proteins in the brain, researchers hope to identify which patients are most likely to benefit from treatment. The study also looks at whether continuing lecanemab helps people whose disease progresses to moderate dementia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lecanemab (a monoclonal antibody given by IV infusion)
What this could lead to
If successful, this could help identify which Alzheimer's patients are most likely to benefit from lecanemab and whether continuing treatment slows decline even in moderate stages.
What could go wrong
This is an early-stage study with only 120 participants, so results may not apply to everyone. Some patients may not respond, and the treatment requires regular IV infusions with potential side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••